Cro industry ushers in the golden development period, these enterprises deserve attention

[pharmaceutical network market analysis] recently, Zhaoyan new drug released the notice of increase in performance in 2019, which said that it is expected to realize the non net profit deduction of 126 million yuan to 144 million yuan attributable to shareholders of Listed Companies in 2019, an increase of about 40% - 60% year on year According to the announcement, the main reason for the performance increase in advance is that the boom of cro industry continues to be good, and the company's orders continue to grow steadily In fact, with the introduction of a series of national pharmaceutical reform policies in recent years, such as the evaluation of the consistency of quality and efficacy of generic drugs, and the procurement with quantity, the industry survival rules have been changed fundamentally More and more domestic pharmaceutical enterprises are in urgent need of transformation The clustering of new drug research and development also indirectly drives the development of cro industry According to some data, the market size of cro industry in China rose rapidly from $2.1 billion in 2014 to $5.9 billion in 2018, with a compound annual growth rate of 29% It is estimated that by 2023, the domestic cro market will reach US $21.4 billion, with an average annual growth rate of 29.8% in 2019-2023 According to this situation, China's cro industry has ushered in a golden development period However, it is worth noting that while the cro industry ushers in good opportunities, it is accompanied by more fierce industry competition The industry believes that in the future, the enterprises that can really benefit from it will be competitive enterprises, such as Wuxi apptec, Zhaoyan new medicine, tiger medicine, kailaiying, etc Founded in December 2000, Wuxi apptec is a globally recognized open, comprehensive and integrated pharmaceutical R & D service capability and technology platform with the strength of new drug R & D Through self establishment, joint venture and M & A, the company has expanded its business scope to small molecule drug cdmo, biological drug R & D and production and other fields, and established its position as the front line of cro + CMO in China The main investment logic of Wuxi apptec is still the industry leader It cooperates with most of the top 20 pharmaceutical companies in the world, with obvious scale effect and less uncertainties Since its listing on the New York Stock Exchange in 2007, it has acquired a number of Companies in the United States and other regions, expanding pre clinical cro businesses such as medical devices and biological preparations Zhaoyan new drug is a pre clinical cro enterprise that provides pharmaceutical R & D outsourcing services for pharmaceutical R & D institutions and pharmaceutical enterprises, and it is in a leading position among pre clinical cro enterprises in China Zhaoyan new drug has two GLP centers in Beijing and Suzhou, as well as a pre clinical evaluation technology platform with a complete GLP quality management system It has 4 subsidiaries Suzhou Zhaoyan and Beijing Zhaoyan (Headquarters) are the same business subjects Guangdong frontier provides related businesses of experimental animals, Zhaoyan California provides overseas businesses, and Shikang frontier provides development services of ophthalmic drugs and medical technology In addition, Zhaoyan new drug has rich project experience in the field of preclinical evaluation of drugs, has completed preclinical research and evaluation tests of more than 2000 drugs, and has rich experience in GLP management and drug safety evaluation As Zhaoyan new drug has a strong voice in the industry, it has also become one of the few enterprises in the industry to charge for advance receipts Tiger Pharma is an early listed cro company with a share Its business focuses on clinical experiments, and its service level can meet the requirements of ICH-GCP and GCP quality specifications at the same time It is in the first group of cro companies in the domestic clinical stage In recent years, tiger pharmaceutical has achieved rapid development through more domestic and overseas M & A, with a large number of international customers (overseas business accounts for about 43%) At present, its overseas business has entered the integration period, and its performance has entered the rapid release stage In addition, on October 29, 2019, tiger Pharma self raised about $17.7433 million to purchase 1.4 million shares of EPS common stock, which will hold 3.06% of EPS after the completion of the transaction It is understood that EPS company is a leading enterprise in Japanese cro industry It mainly provides various high added value solutions for many customers, such as pharmaceutical companies, medical device manufacturers, new drug R & D companies, medical institutions, university research institutions, etc., to support the product development of customers In the future, the development of tiger's international business will be further promoted to help enhance its global competitiveness Kailaiying kailaiying is a cdmo (customized R & D and production of pharmaceutical contracts) solution provider and A-share listed CMO company It mainly focuses on technological innovation and commercial application of global pharmaceutical technology, and provides one-stop CMC service for large and medium-sized pharmaceutical enterprises and biotechnology enterprises at home and abroad Its main customers are mosadong, Pfizer, Bristol Myers Squibb, Aberdeen, Lilly and other large and medium-sized pharmaceutical companies in the world The drugs served (from the company's annual report) include drugs for major diseases such as anti hepatitis C, anti diabetes, antilipidemic statins, as well as drugs with great technical difficulties such as anti-cancer and the second generation of anti AIDS drugs Some of the drugs have become breakthrough new drugs in the world.